Key facts
- It has raised $183.6M; the latest was General Corporate Purpose ($60.0M) in Jul 2025.
- Notable investors include FJ Labs, SV Angel, Kevin Moore, Forerunner Ventures, Hemisphere Ventures — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Phil
- ·The full record, as it builds
Funding rounds
No funding rounds for Phil are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phil
Developer of an end-to-end healthcare platform designed to make specialty drugs more available and affordable to consumers. The company's platform connects patients, prescribers, pharmacies, and manufacturers and provides an end-to-end prescription management service as a convenient alternative to traditional pharmaceutical management, enabling patients to get access to low-cost medicines and better outcomes for rare diseases.
- Sector
- Healthcare
- HQ
- Scottsdale, AZ, United States
- Founded
- 2015
- Employees
- 195
- Website
- phil.us/
- Ownership
- Privately Held (backing)
Phil doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phil shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phil in its N-PORT filings yet. We sweep new filings monthly.